Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial (Q33872486)

29 July 2017

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial (English)

1 reference

29 July 2017

0 references

1 reference

B J Rembacken

1

1 reference

29 July 2017

A M Snelling

2

1 reference

29 July 2017

P M Hawkey

3

1 reference

29 July 2017

D M Chalmers

4

1 reference

29 July 2017

A T Axon

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

29 July 2017

1 reference

29 July 2017

354

1 reference

29 July 2017

635-639

1 reference

29 July 2017

9179

1 reference

Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Rectal biopsy in patients presenting to an infectious disease unit with diarrhoeal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Properties of strains of Escherichia coli isolated from the faeces of patients with ulcerative colitis, patients with acute diarrhoea and normal persons.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Ulcerative colitis and Escherichia coli with adhesive properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

The efficacy of tobramycin in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Oral tobramycin in ulcerative colitis: effect on maintenance of remission.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Cortisone in ulcerative colitis; final report on a therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

TREATMENT OF ULCERATIVE COLITIS BY IMPLANTATION OF NORMAL COLONIC FLORA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

Properties of Escherichia coli strains of serotype O6.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2906343-0

7 January 2021

10.1016/S0140-6736(98)06343-0

Identifiers

DOI

1 reference

29 July 2017

1 reference